-

QIAGEN N.V. to Report Fourth Quarter and Full Year 2019 Results

VENLO, the Netherlands--(BUSINESS WIRE)--QIAGEN N.V. (NYSE: QGEN) (Frankfurt Stock Exchange: QIA) announced today that it plans as previously announced to release its report on results for the fourth quarter and full-year 2019 on Tuesday, February 4, at approximately 22:05 Central European Time (CET) / 16:05 Eastern Standard Time (EST).

A conference call is planned for Wednesday, February 5, at 15:00 CET / 9:00 EST hosted by Thierry Bernard, Senior Vice President, Head of Molecular Diagnostics Business Area, and Interim CEO, and Roland Sackers, Chief Financial Officer.

Conference call and webcast details

The conference call will begin at 15:00 CET / 9:00 EST on Wednesday, February 5, 2020.

Interested parties may listen to the call by dialing:

+1 646 828 8193 (U.S.), +44 (0)330 336 9126 (UK), +49 (0)69 2222 25575 (Germany).

To avoid waiting time, please join the event conference 5-10 minutes prior to the start time.

Conference ID: 2139086

The webcast will be accessible at:

https://globalmeet.webcasts.com/starthere.jsp?ei=1279315&tp_key=b4903b138d

A conference call replay will be available by using the following link:

https://globalmeet.webcasts.com/starthere.jsp?ei=1279315&tp_key=b4903b138d

Contact: IR@qiagen.com

About QIAGEN

QIAGEN N.V., a Netherlands-based holding company, is the leading global provider of Sample to Insight solutions that enable customers to gain valuable molecular insights from samples containing the building blocks of life. Our sample technologies isolate and process DNA, RNA and proteins from blood, tissue and other materials. Assay technologies make these biomolecules visible and ready for analysis. Bioinformatics software and knowledge bases interpret data to report relevant, actionable insights. Automation solutions tie these together in seamless and cost-effective workflows. QIAGEN provides solutions to more than 500,000 customers around the world in Molecular Diagnostics (human healthcare) and Life Sciences (academia, pharma R&D and industrial applications, primarily forensics). As of September 30, 2019, QIAGEN employed approximately 5,200 people in over 35 locations worldwide.

Further information can be found at http://www.qiagen.com.

Contacts

John Gilardi
Vice President Corporate Communications and Investor Relations
+49 2103 29 11711
+1 240 686 2222
Email: ir@qiagen.com

Phoebe Loh
Associate Director Investor Relations
+49 2103 29 11457
Email: ir@qiagen.com

Industry:

QIAGEN N.V.

NYSE:QGEN
Details
Headquarters: Venlo, Netherlands
CEO: Thierry Bernard
Employees: 5800
Organization: PUB
Revenues: US$ 1.97 billion (2023)
Net Income: US$ 341.3 million (2023)
Release Summary
QIAGEN N.V. to Report Fourth Quarter and Full Year 2019 Results
Release Versions
English

Contacts

John Gilardi
Vice President Corporate Communications and Investor Relations
+49 2103 29 11711
+1 240 686 2222
Email: ir@qiagen.com

Phoebe Loh
Associate Director Investor Relations
+49 2103 29 11457
Email: ir@qiagen.com

More News From QIAGEN N.V.

Parse Biosciences Launches Evercode Whole Transcriptome V4 With Shorter Workflow, Higher Sensitivity and Higher Cell Recovery

SEATTLE, Wash. & VENLO, the Netherlands--(BUSINESS WIRE)--Parse Biosciences, a QIAGEN company (NYSE: QGEN, Frankfurt Prime Standard: QIA), and the leading provider of scalable and accessible single-cell sequencing solutions today announced the launch of the new Evercode™ Whole Transcriptome v4 product line, delivering expanded scalability, higher sensitivity and a simplified workflow for single-cell RNA sequencing. Evercode v4 supports extraordinary scalability of up to five million cells and 3...

QIAGEN Exceeds Q4 2025 Outlook Driven by Growth Pillars

VENLO, Netherlands--(BUSINESS WIRE)--QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) today announced results for the fourth quarter and full-year 2025. Net sales for Q4 2025 rose 4% to $540 million, with sales at constant exchange rates (CER) up 1% and exceeding the outlook for steady CER results compared to the year-ago period while overcoming macroeconomic challenges and the impact of the 2025 U.S. government shutdown. Solid ongoing trends among the growth pillars, which rose 7% CER,...

QIAGEN Showcases QIAsprint Connect High-Throughput Automation System for Labs Worldwide at SLAS 2026

GERMANTOWN, Md. & VENLO, Netherlands--(BUSINESS WIRE)--QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) today announced the first public showcase of QIAsprint Connect at SLAS 2026 in Boston, marking QIAGEN’s entry into high-throughput benchtop automation for sample processing in research laboratories. QIAsprint Connect is designed to help labs process large batches of samples efficiently while retaining control over protocols and reducing environmental footprint. The compact system suppo...
Back to Newsroom